150 related articles for article (PubMed ID: 25151801)
21. Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
Becker DJ; Wisnivesky JP; Grossbard ML; Chachoua A; Camidge DR; Levy BP
Clin Lung Cancer; 2017 Jan; 18(1):e35-e40. PubMed ID: 28029530
[TBL] [Abstract][Full Text] [Related]
22. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Ye X; Zhu ZZ; Zhong L; Lu Y; Sun Y; Yin X; Yang Z; Zhu G; Ji Q
J Thorac Oncol; 2013 Sep; 8(9):1118-20. PubMed ID: 23945382
[No Abstract] [Full Text] [Related]
23. [The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)].
;
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):796-9. PubMed ID: 26813604
[No Abstract] [Full Text] [Related]
24. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.
Shackelford RE; Ansari JM; Wei EX; Alexander JS; Cotelingam J
Pharmacogenomics; 2017 Aug; 18(12):1179-1192. PubMed ID: 28745554
[TBL] [Abstract][Full Text] [Related]
27. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.
Shen C; Kehl KL; Zhao B; Simon GR; Zhou S; Giordano SH
Clin Lung Cancer; 2017 Jul; 18(4):e233-e241. PubMed ID: 28024927
[TBL] [Abstract][Full Text] [Related]
28.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
Ther Adv Respir Dis; 2020; 14():1753466620918192. PubMed ID: 32401173
[TBL] [Abstract][Full Text] [Related]
29. Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition).
Society of Cancer Precision Medicine of Chinese Anti-Cancer Association; The Lung Cancer Expert Group of Chinese Medical Association Publishing House
Chin Med J (Engl); 2024 May; 137(9):1016-1018. PubMed ID: 38454303
[No Abstract] [Full Text] [Related]
30. Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Li J; Wang Z; Groen HJM; Zhao J; Wang P; Zhang C; Yang K; Guo Y; Ma J
Lung Cancer; 2018 Apr; 118():173-175. PubMed ID: 29502892
[No Abstract] [Full Text] [Related]
31. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
32. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
[TBL] [Abstract][Full Text] [Related]
33. EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer?
Mitsudomi T; Tada H
J Thorac Oncol; 2012 Dec; 7(12):1739-1741. PubMed ID: 23154542
[No Abstract] [Full Text] [Related]
34. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou SH
J Clin Pathol; 2013 Oct; 66(10):839-46. PubMed ID: 23661716
[TBL] [Abstract][Full Text] [Related]
35. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
36. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
37. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
[TBL] [Abstract][Full Text] [Related]
38. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Gazdar AF
Medicine (Baltimore); 2011 May; 90(3):168-170. PubMed ID: 21512415
[No Abstract] [Full Text] [Related]
40. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
